U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137481) titled 'Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies' on Aug. 15.
Brief Summary: To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Study Start Date: Feb. 28, 2026
Study Type: INTERVENTIONAL
Condition:
Hematological Malignancies
Intervention:
DRUG: C9/CD5CAR/IL-15 NK cells
Given PO or IV
DRUG: Rituximab
Given by IV
DRUG: Fludarabine
Given by IV
DRUG: Cyclophosphamide
G...